Putluri Lab Publications

Publications

Highlighted Articles from Dr. Putluri Lab:

  1.  Amara CS, Kami Reddy KR, Yuntao Y, Chan YS, Piyarathna DWB, Dobrolecki LE, Shih DJH, Shi Z, Xu J, Huang S, Ellis MJ, Apolo AB, Ballester LY, Gao J, Hansel DE, Lotan Y, Hodges HC, Lerner SP, Creighton CJ, Sreekumar A, Zheng WJ, Msaouel P, Kavuri SM, Putluri N. The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer. Nat Commun. 2024;15(1):1373. doi:10.1038/s41467-024-45132-2. 
  2. Kami Reddy KR, Putluri V, Piyarathna DWB, Park JH, Arun AK, Jorvekar SB, Dou Y, Hassan MK, Amara CS, Kamal AHM, Ambati CSR, Xu J, Kraushaar D, Gramer AL, Bellman AC, Ballester LY, Xu Y, Ripley RT, Lerner SP, Bollag RJ, Terris MK, Pan CX, Kaipparettu BA, Lotan Y, Putluri N. Oncogenic PIK3CA reprograms glutamine metabolism to drive bladder cancer progression. Cell Commun Signal. 2026 (in press). doi:10.1186/s12964-026-03058-w.
  3. Amara CS, Piyarathna DWB, Kamal AHM, et al. Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression. Cancer Lett. 2026;653:218562. doi:10.1016/j.canlet.2026.218562. 
  4. Kami Reddy KR, Piyarathna DWB, Park JH, Putluri V, Amara CS, Kamal AHM, Xu J, Kraushaar D, Huang S, Jung SY, Eberlin LS, Johnson JR, Kittles RA, Ballester LY, Parsawar K, Siddiqui MM, Gao J, Gramer AL, Bollag RJ, Terris MK, Lotan Y, Creighton CJ, Lerner SP, Sreekumar A, Kaipparettu BA, Putluri N. Mitochondrial reprogramming by activating OXPHOS via glutamine metabolism in African American patients with bladder cancer. JCI Insight. 2024;9(17):e172336. doi:10.1172/jci.insight.172336.
  5. Kamal AHM, Putluri V, Gandhi T, Ambati CSR, Amara CS, Kami Reddy KR, Spradlin ML, Koirala A, Jorvekar SB, Grimm SL, Fu D, Parsawar K, de Jong F, Beecher C, Sen S, Lerner SP, Siddiqui MM, Lotan Y, Eberlin LS, Sreekumar A, Coarfa C, Putluri N. Leveraging untargeted metabolomics in combination with machine learning to uncover novel insights into bladder cancer. Cancer Metab. 2026 Apr 1;14(1):8. doi: 10.1186/s40170-026-00427-4. PMID: 41923172; PMCID: PMC13040883. 
  6. Vantaku V, Dong J, Ambati CR, Perera D, Donepudi SR, Amara CS, Putluri V, Shankar RV, Robertson MJ, Piyarathna DWB, Villanueva M, von Rundstedt FC, Karanam B, Ballester LY, Terris MK, Bollag RJ, Lerner SP, Andrea AB, Villanueva H, Lee M, Sikora AG, Lotan Y, Sreekumar A, Coarfa C, Putluri N. Multi-omics integration analysis robustly predicts high-grade patient survival and identifies CPT1B effect on fatty acid metabolism in bladder cancer. Clin Cancer Res. 2019;25(12):3689-3701. doi:10.1158/1078-0432.CCR-18-1515. 
  7. Vantaku V, Putluri V, Bader DA, Maity S, Ma J, Arnold JM, Rajapakshe K, Donepudi SR, von Rundstedt FC, Devarakonda V, Dubrulle J, Karanam B, McGuire SE, Stossi F, Jain AK, Coarfa C, Cao Q, Sikora AG, Villanueva H, Kavuri SM, Lotan Y, Sreekumar A, Putluri N. Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. Oncogene. 2020;39(40):6265-6285. doi:10.1038/s41388-019-0902-7. 
  8. Vantaku V, Amara CS, Piyarathna DWB, Donepudi SR, Ambati CR, Putluri V, Tang W, Rajapakshe K, Estecio MR, Terris MK, Castro PD, Ittmann MM, Williams SB, Lerner SP, Sreekumar A, Bollag R, Coarfa C, Kornberg MD, Lotan Y, Ambs S, Putluri N. DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism. Carcinogenesis. 2019 Nov 25;40(11):1332-1340. doi: 10.1093/carcin/bgz128. PMID: 31284295; PMCID: PMC6875901. 
  9. Vantaku V, Dong J, Ambati CR, Perera D, Donepudi SR, Amara CS, Putluri V, Ravi SS, Robertson MJ, Piyarathna DWB, Villanueva M, von Rundstedt FC, Karanam B, Ballester LY, Terris MK, Bollag RJ, Lerner SP, Apolo AB, Villanueva H, Lee M, Sikora AG, Lotan Y, Sreekumar A, Coarfa C, Putluri N. Multi-omics integration analysis robustly predicts high-grade patient survival and identifies CPT1B effect on fatty acid metabolism in bladder cancer. Clin Cancer Res. 2019 Jun 15;25(12):3689-3701. doi: 10.1158/1078-0432.CCR-18-1515. Epub 2019 Mar 7. PMID: 30846479; PMCID: PMC6571061. 
  10. Amara CS, Ambati CR, Vantaku V, Piyarathna DWB, Donepudi SR, Ravi SS, Arnold JM, Putluri V, Chatta G, Guru KA, Badr H, Terris MK, Bollag RJ, Sreekumar A, Apolo AB, Putluri N. Serum metabolic profiling identified a distinct metabolic signature in bladder cancer smokers: a key metabolic enzyme associated with patient survival. Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):770-781. doi: 10.1158/1055-9965.EPI-18-0936. Epub 2019 Jan 14. PMID: 30642841; PMCID: PMC6449217. 
  11. Vantaku V, Donepudi SR, Piyarathna DWB, Amara CS, Ambati CR, Tang W, Putluri V, Chandrashekar DS, Varambally S, Terris MK, Davies K, Ambs S, Bollag R, Apolo AB, Sreekumar A, Putluri N. Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival. Cancer. 2019 Mar 15;125(6):921-932. doi: 10.1002/cncr.31890. Epub 2019 Jan 2. PMID: 30602056; PMCID: PMC6402983. 
  12. Vantaku V, Donepudi SR, Ambati CR, Jin F, Putluri V, Nguyen K, Rajapakshe K, Coarfa C, Battula VL, Lotan Y, Putluri N. Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer. Oncotarget. 2017 Sep 16;8(56):95620-95631. doi: 10.18632/oncotarget.21038. eCollection 2017 Nov 10. Erratum in: Oncotarget. 2019 Nov 26;10(63):6843-6844. doi: 10.18632/oncotarget.27311. PMID: 29221154; PMCID: PMC5707048. 
  13. Piyarathna DWB, Rajendiran TM, Putluri V, Vantaku V, Soni T, von Rundstedt FC, Donepudi SR, Jin F, Maity S, Ambati CR, Dong J, Gödde D, Roth S, Störkel S, Degener S, Michailidis G, Lerner SP, Pennathur S, Lotan Y, Coarfa C, Sreekumar A, Putluri N. Distinct lipidomic landscapes associated with clinical stages of urothelial cancer of the bladder. Eur Urol Focus. 2018 Dec;4(6):907-915. doi: 10.1016/j.euf.2017.04.005. Epub 2017 Apr 20. Erratum in: Eur Urol Focus. 2019 Sep;5(5):920. doi: 10.1016/j.euf.2019.08.010. PMID: 28753886; PMCID: PMC5650548. 
  14. von Rundstedt FC, Rajapakshe K, Ma J, Arnold JM, Gohlke J, Putluri V, Krishnapuram R, Piyarathna DB, Lotan Y, Gödde D, Roth S, Störkel S, Levitt JM, Michailidis G, Sreekumar A, Lerner SP, Coarfa C, Putluri N. Integrative pathway analysis of metabolic signature in bladder cancer: a linkage to The Cancer Genome Atlas Project and prediction of survival. J Urol. 2016 Jun;195(6):1911-1919. doi: 10.1016/j.juro.2016.01.039. Epub 2016 Jan 21. PMID: 26802582; PMCID: PMC4861129. 
  15. Putluri N, Shojaie A, Vasu VT, Vareed SK, Nalluri S, Putluri V, Thangjam GS, Panzitt K, Tallman CT, Butler C, Sana TR, Fischer SM, Sica G, Brat DJ, Shi H, Palapattu GS, Lotan Y, Weizer AZ, Terris MK, Shariat SF, Michailidis G, Sreekumar A. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res. 2011 Dec 15;71(24):7376-7386. doi: 10.1158/0008-5472.CAN-11-1154. Epub 2011 Oct 11. PMID: 21990318; PMCID: PMC3249241.

Notable Collaborative Articles from Dr. Putluri Lab:

  1. Sahu U, Mullarkey MP, Murphy SA, Anderson JC, Putluri V, Kamal AHM, Park JH, Lee TJ, Ling AL, Kaipparettu BA, Sharma A, Putluri N, Wenzel PL, Willey CD, Chiocca EA, Markert JM, Kaur B. IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunity. Nat Commun. 2025 Apr 24;16(1):3874. doi: 10.1038/s41467-025-58911-2. PMID: 40274791; PMCID: PMC12022073.
  2. Li Y, Yadollahi P, Essien FN, Putluri V, Ambati CSR, Kami Reddy KR, Kamal AHM, Putluri N, Abdurrahman LM, Ruiz Echartea ME, Ernste KJ, Trivedi AJ, Vazquez-Perez J, Hudson WH, Decker WK, Patel R, Osman AA, Kheradmand F, Lai SY, Myers JN, Skinner HD, Coarfa C, Lee K, Jain A, Malovannaya A, Frederick MJ, Sandulache VC. Tobacco smoke exposure is a driver of altered oxidative stress response and immunity in head and neck cancer. J Transl Med. 2025 Apr 5;23(1):403. doi: 10.1186/s12967-025-06258-z. PMID: 40188338; PMCID: PMC11971752.
  3. Park JH, Jung KH, Jia D, Yang S, Attri KS, Ahn S, Murthy D, Samanta T, Dutta D, Ghidey M, Chatterjee S, Han SY, Pedroza DA, Tiwari A, Lee JV, Davis C, Li S, Putluri V, Creighton CJ, Putluri N, Dobrolecki LE, Lewis MT, Rosen JM, Onuchic JN, Goga A, Kaipparettu BA. Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway. Cell Rep Med. 2025 Feb 18;6(2):101941. doi: 10.1016/j.xcrm.2025.101941. Epub 2025 Feb 10. PMID: 39933530; PMCID: PMC11866546.
  4. Meena JK, Wang JH, Neill NJ, Keough D, Putluri N, Katsonis P, Koire AM, Lee H, Bowling EA, Tyagi S, Orellana M, Dominguez-Vidaña R, Li H, Eagle K, Danan C, Chung HC, Yang AD, Wu W, Kurley SJ, Ho BM, Zoeller JR, Olson CM, Meerbrey KL, Lichtarge O, Sreekumar A, Dacso CC, Guddat LW, Rejman D, Hocková D, Janeba Z, Simon LM, Lin CY, Pillon MC, Westbrook TF. MYC Induces Oncogenic Stress through RNA Decay and Ribonucleotide Catabolism in Breast Cancer. Cancer Discov. 2024 Sep 4;14(9):1699-1716. doi: 10.1158/2159-8290.CD-22-0649. PMID: 39193992; PMCID: PMC11372365.
  5. Murthy D, Dutta D, Attri KS, Samanta T, Yang S, Jung KH, Latario SG, Putluri V, Huang S, Putluri N, Park JH, Kaipparettu BA. CD24 negativity reprograms mitochondrial metabolism to PPARα and NF-κB-driven fatty acid β-oxidation in triple-negative breast cancer. Cancer Lett. 2024 Apr 10;587:216724. doi: 10.1016/j.canlet.2024.216724. Epub 2024 Feb 17. PMID: 38373689; PMCID: PMC11068061.
  6. Nguyen T, Sridaran D, Chouhan S, Weimholt C, Wilson A, Luo J, Li T, Koomen J, Fang B, Putluri N, Sreekumar A, Feng FY, Mahajan K, Mahajan NP. Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer. Nat Commun. 2023 Jun 9;14(1):3357. doi: 10.1038/s41467-023-38887-7. Erratum in: Nat Commun. 2023 Sep 27;14(1):6022. doi: 10.1038/s41467-023-41810-9. PMID: 37296155; PMCID: PMC10256812.
  7. Chang CY, You R, Armstrong D, Bandi A, Cheng YT, Burkhardt PM, Becerra-Dominguez L, Madison MC, Tung HY, Zeng Z, Wu Y, Song L, Phillips PE, Porter P, Knight JM, Putluri N, Yuan X, Marcano DC, McHugh EA, Tour JM, Catic A, Maneix L, Burt BM, Lee HS, Corry DB, Kheradmand F. Chronic exposure to carbon black ultrafine particles reprograms macrophage metabolism and accelerates lung cancer. Sci Adv. 2022 Nov 18;8(46):eabq0615. doi: 10.1126/sciadv.abq0615. Epub 2022 Nov 16. PMID: 36383649; PMCID: PMC9668323.
  8. Odunsi K, Qian F, Lugade AA, Yu H, Geller MA, Fling SP, Kaiser JC, Lacroix AM, D'Amico L, Ramchurren N, Morishima C, Disis ML, Dennis L, Danaher P, Warren S, Nguyen VA, Ravi S, Tsuji T, Rosario S, Zha W, Hutson A, Liu S, Lele S, Zsiros E, McGray AJR, Chiello J, Koya R, Chodon T, Morrison CD, Putluri V, Putluri N, Mager DE, Gunawan R, Cheever MA, Battaglia S, Matsuzaki J. Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Sci Transl Med. 2022 Mar 16;14(636):eabg8402. doi: 10.1126/scitranslmed.abg8402. Epub 2022 Mar 16. PMID: 35294258; PMCID: PMC9311231.
  9. Tao L, Moreno-Smith M, Ibarra-García-Padilla R, Milazzo G, Drolet NA, Hernandez BE, Oh YS, Patel I, Kim JJ, Zorman B, Patel T, Kamal AHM, Zhao Y, Hicks J, Vasudevan SA, Putluri N, Coarfa C, Sumazin P, Perini G, Parchem RJ, Uribe RA, Barbieri E. CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming. Adv Sci (Weinh). 2021 Oct;8(19):e2005047. doi: 10.1002/advs.202005047. Epub 2021 Aug 8. PMID: 34365742; PMCID: PMC8498874.
  10. Moreno-Smith M, Milazzo G, Tao L, Fekry B, Zhu B, Mohammad MA, Di Giacomo S, Borkar R, Reddy KRK, Capasso M, Vasudevan SA, Sumazin P, Hicks J, Putluri N, Perini G, Eckel-Mahan K, Burris TP, Barbieri E. Restoration of the molecular clock is tumor suppressive in neuroblastoma. Nat Commun. 2021 Jun 28;12(1):4006. doi: 10.1038/s41467-021-24196-4. PMID: 34183658; PMCID: PMC8238982.
    26.    Sawant Dessai A, Dominguez MP, Chen UI, Hasper J, Prechtl C, Yu C, Katsuta E, Dai T, Zhu B, Jung SY, Putluri N, Takabe K, Zhang XH, O'Malley BW, Dasgupta S. Transcriptional Repression of SIRT3 Potentiates Mitochondrial Aconitase Activation to Drive Aggressive Prostate Cancer to the Bone. Cancer Res. 2021 Jan 1;81(1):50-63. doi: 10.1158/0008-5472.CAN-20-1708. Epub 2020 Oct 28. PMID: 33115805; PMCID: PMC7878313.
  11. Treviño LS, Dong J, Kaushal A, Katz TA, Jangid RK, Robertson MJ, Grimm SL, Ambati CSR, Putluri V, Cox AR, Kim KH, May TD, Gallo MR, Moore DD, Hartig SM, Foulds CE, Putluri N, Coarfa C, Walker CL. Epigenome environment interactions accelerate epigenomic aging and unlock metabolically restricted epigenetic reprogramming in adulthood. Nat Commun. 2020 May 8;11(1):2316. doi: 10.1038/s41467-020-15847-z. PMID: 32385268; PMCID: PMC7210260.
  12. Dey P, Li J, Zhang J, Chaurasiya S, Strom A, Wang H, Liao WT, Cavallaro F, Denz P, Bernard V, Yen EY, Genovese G, Gulhati P, Liu J, Chakravarti D, Deng P, Zhang T, Carbone F, Chang Q, Ying H, Shang X, Spring DJ, Ghosh B, Putluri N, Maitra A, Wang YA, DePinho RA. Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. Cancer Discov. 2020 Apr;10(4):608-625. doi: 10.1158/2159-8290.CD-19-0297. Epub 2020 Feb 11. PMID: 32046984; PMCID: PMC7125035.